ArticleWorld journal of gastrointestinal surgery2026
Post-chemotherapy C-reactive protein/albumin ratio predicts prognosis in stage II-III colorectal cancer.
Article in World journal of gastrointestinal surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. The C-reactive protein/albumin ratio (CAR) has emerged as a potential prognostic marker in various cancers. Nonetheless, if the post-surgical drug therapy CAR is a beneficial predictive component in individuals with CRC remains unclear.
aimTo investigate the prognostic value of post-adjuvant chemotherapy CAR in comparison with preoperative CAR and other inflammatory markers in patients with stage II-III CRC.
methodsThis retrospective study included 445 patients with CRC that experienced anti-cancer therapy subsequent to definitive excision. Pre-surgical and post-adjuvant therapeutic regimen CAR, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated to assess the inflammatory state of the patients. First, patients were divided into two groups based on the CAR, NLR, PLR, and SII values. Furthermore, patients were partitioned into four clusters for every parameter based on the long-term variations in measures from before surgery to after chemotherapy: Low, normalized, high, and elevated groups. Multiple studies concerning overall survival (OS) were executed to compensate for well-documented clinicopathological factors. Kaplan-Meier method and Cox regression approaches were applied to evaluate distinct predictive factor.
resultsPost-adjuvant chemotherapy CAR demonstrated the highest area under the curve value (0.8175) among all inflammatory markers for predicting OS. Post-adjuvant chemotherapy inflammatory markers (CAR, NLR, PLR, and SII) showed significantly higher area under the curve values than their preoperative counterparts. Longitudinal analysis revealed that a reduced inflammatory cohort exhibited markedly superior OS than an elevated inflammatory cohort regarding every indicator (all
conclusionThese results indicate that post-adjuvant chemotherapy CAR is superior to preoperative measurements and other systemic inflammation-based prognostic scores in predicting outcomes for patients with stage II-III CRC. Longitudinal monitoring of inflammatory markers, particularly CAR, provides valuable prognostic information and may guide clinical decision-making in the post-treatment surveillance period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.